Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 8/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8557026 | 1.00 | CARM1 (0.55) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL24322383 | 0.80 | KDM4E (0.45) | HTR7HRH3 | |
| SCHEMBL24322614 | 0.80 | KDM4E (0.45) | HTR7HRH3 | |
| SCHEMBL24322756 | 0.80 | KDM4E (0.45) | HTR7HRH3 | |
| SCHEMBL24322393 | 0.80 | KDM4E (0.45) | HTR7HRH3 | |
| SCHEMBL8085877 | 0.79 | CARM1 (0.52) | CARM1PRMT6PRMT1PRMT8SIGMAR1 | |
| SCHEMBL9274604 | 0.79 | CARM1 (0.48) | CARM1PRMT6PRMT8HRH3 | |
| SCHEMBL8594059 | 0.78 | CARM1 (0.46) | CARM1PRMT6PRMT8POLBHRH3 | |
| SCHEMBL28642601 | 0.78 | PAOX (0.33) | CARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL24319341 | 0.78 | CARM1 (0.50) | CARM1PRMT6PRMT1PRMT8SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-0883613-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-12-16 | — | — | EP | disclosed |
| WO-1997029097-A1 | SULFONAMIDE DERIVATIVES AS 5HT7 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | CARM1 4394/4885PRMT6 2880/4885PRMT1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.